gs-4071 and Liver-Cirrhosis

gs-4071 has been researched along with Liver-Cirrhosis* in 1 studies

Other Studies

1 other study(ies) available for gs-4071 and Liver-Cirrhosis

Article	Year
Simulation of the Pharmacokinetics of Oseltamivir and Its Active Metabolite in Normal Populations and Patients with Hepatic Cirrhosis Using Physiologically Based Pharmacokinetic Modeling. AAPS PharmSciTech, 2020, Mar-03, Volume: 21, Issue:3 Oseltamivir is a neuraminidase inhibitor widely used to treat and prevent influenza A and B infections, although its safety and pharmacokinetics have not been evaluated in patients with severe hepatic impairment. A physiologically based pharmacokinetic (PBPK) model of the prodrug oseltamivir and its active metabolite, oseltamivir carboxylate (OC), was established and validated to simulate their disposition in adults and predict the exposure in patients with Child-Pugh C cirrhosis (CP-C). The simulated results from PBPK modeling and the observed data after oral administration of various oseltamivir regimens were consistent according to the fold error values of less than 2. Furthermore, the clinical observations published in the literature were comparable with our pharmacokinetic predictions. In patients with CP-C, the oseltamivir C Topics: Administration, Oral; Adolescent; Adult; Aged; Antiviral Agents; Computer Simulation; Enzyme Inhibitors; Female; Humans; Liver Cirrhosis; Male; Middle Aged; Models, Biological; Oseltamivir; Prodrugs; Young Adult	2020

Article

Year

Simulation of the Pharmacokinetics of Oseltamivir and Its Active Metabolite in Normal Populations and Patients with Hepatic Cirrhosis Using Physiologically Based Pharmacokinetic Modeling.

AAPS PharmSciTech, 2020, Mar-03, Volume: 21, Issue:3

Oseltamivir is a neuraminidase inhibitor widely used to treat and prevent influenza A and B infections, although its safety and pharmacokinetics have not been evaluated in patients with severe hepatic impairment. A physiologically based pharmacokinetic (PBPK) model of the prodrug oseltamivir and its active metabolite, oseltamivir carboxylate (OC), was established and validated to simulate their disposition in adults and predict the exposure in patients with Child-Pugh C cirrhosis (CP-C). The simulated results from PBPK modeling and the observed data after oral administration of various oseltamivir regimens were consistent according to the fold error values of less than 2. Furthermore, the clinical observations published in the literature were comparable with our pharmacokinetic predictions. In patients with CP-C, the oseltamivir C

Topics: Administration, Oral; Adolescent; Adult; Aged; Antiviral Agents; Computer Simulation; Enzyme Inhibitors; Female; Humans; Liver Cirrhosis; Male; Middle Aged; Models, Biological; Oseltamivir; Prodrugs; Young Adult

2020